Brentwood, Tenn.-February 5, 2009-Praxis, a company specializing in centralized patient recruitment for clinical research studies, recently provided patient recruitment services to a global pharmaceutical company for a study to test an investigational medication for a mental health indication. The recruitment program saved a combined 15 months for the 2-protocol program and delivered an 891% return on investment for one protocol and 539% return on investment for the second protocol.
Through Praxis’ upfront protocol feasibility analysis and target audience research, a customized & integrated marketing campaign was developed to increase awareness of the study in the communities surrounding the 90 participating clinical research sites. With only 75% of potential sites activating, 97% of total screenings and randomizations came from the Praxis supported sites utilizing the strategic marketing campaign which consisted of direct to patient branded advertising, on-site recruitment materials and electronic/online strategies.
Additionally, a comprehensive retention campaign was launched to encourage study compliance and completion by each subject. This resulted in a 91% retention rate-which is 30% greater than the industry average for phase III studies.
Praxis Communications, Inc., headquartered in Brentwood, Tenn., provides the pharmaceutical and biotech industries with a wide range of global services for patient recruitment and retention for clinical trials including patient profiling, recruitment planning, centralized fulfillment, media relations, advertising, and program management. For more information, call Praxis at (615) 312-8207 or visit www.GoPraxis.com.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.